I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
Chiron Corp. |
F. Hoffmann-La Roche Ltd. (Switzerland) |
They settled dispute on royalty revenues owed to Chiron under its patent on nucleic acid testing methods for HIV |
Under the settlement, which covers diagnostics and blood screening, Roche stipulates to the validity of the patent and will pay Chiron $78M in lieu of royalties beyond Jan. 1, 2005 (9/10) |
Dharmacon Inc.* |
Wyeth Pharmaceuticals |
Dharmacon will supply custom siRNA reagents to the genomics research operations at Wyeth |
The deal expands and extends their relationship, which began in December 2002; terms were not disclosed (9/8) |
Gen-Probe Inc. (GPRO) |
Vysis Inc. (subsidiary of Abbott Laboratories) |
They settled patent litigation on amplified products for clinical diagnostics and blood screening |
Gen-Probe will pay $22.5M, and not have to pay any royalties after 3Q:04; Gen-Probe has been paying a 3% royalty since 1999 (9/23) |
Intercell AG* (Austria) |
Aventis-Pasteur (France) |
Extended collaboration to develop bacterial vaccines |
Intercell will further develop antigens it identified in their February 2004 deal; terms were not disclosed (8/31) |
ISTA |
Allergan Inc. |
ISTA reacquired all rights to Vitrase for all uses in the U.S. and certain other markets under an amendment to their March 2000 deal |
ISTA will pay Allergan $10M and royalties on U.S. sales of Vitrase used in the posterior segment of the eye; Allergan retains an option on the product in Europe (9/28) |
Norak |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Roche exercised its second- year option to screen more GPCR targets using Norak's Transfluor technology |
The option was part of their September 2002 agreement; terms were not disclosed (9/8) |
Nuvelo Inc. |
Kirin Brewery Co. Ltd. (Japan) |
Extended and expanded deal to include additional secreted protein genes from Nuvelo's full-length gene portfolio |
The collaboration was extended to Dec. 31, 2005; Kirin will use its transgenic mouse technology to identify proteins and associated antibodies with therapeutic utility; terms were not disclosed (9/15) |
Odyssey |
Merck & Co. Inc. |
Expanded deal using Odyssey's technology to elucidate the full spectrum of Merck compounds in human cells |
The goal is to characterize the on-pathway and off-pathway effects of compounds early in the discovery process; terms were not disclosed (10/8) |
Tripos Inc. (TRPS) |
Schering AG (Germany) |
They extended a contract governing development of a chemical information management system |
The new deal provides Tripos with increased funding and includes milestone payments; system deployment is expected in 2005 (9/30) |
Xenogen Corp. |
Merck & Co. Inc. |
Expanded deal under which Merck will purchase five biophotonic imaging systems and the accompanying software |
Merck will use the systems in cancer R&D under the five-year global license, which extended a deal between the companies (10/12) |
II. TERMINATED AGREEMENTS | |||
Advancis |
GlaxoSmithKline plc (UK) |
GSK is ending a deal to use Advancis' Pulsys technology with its Augmentin products effective Dec. 15, 2004 |
Advancis will have received $11.5M from GSK in the July 2003 deal that could have meant $49M in development milestones and $50M in sales milestones to Advancis (10/19) |
Connetics |
UCB Pharma Inc. (Belgium) |
UCB opted out of a co-promotion agreement for Olux and Luxiq |
UCB will stop promoting the products to certain primary care physicians effective March 31, 2005 (10/14) |
Flamel |
Bristol-Myers Squibb Co. |
They terminated August 2003 license agreement for Flamel's formulation of long- acting human insulin |
Flamel plans to seek a new partner for the program (9/16) |
Microbix |
Undisclosed vaccine producer |
No agreement was reached on deal for influenza virus yield-enhancement technology following 103-day review |
Microbix will get $600,000 following the end of the exclusive review and negotiation period (9/29) |
NeoPharm Inc. (NEOL) |
Pfizer Inc. |
They are ending deal to develop liposome- encapsulated paclitaxel and liposome-encapsulated doxorubicin |
NeoPharm regains all rights to LEP and LED, as well as to the rights to develop liposomal formulations of other taxane and anthracycline drugs (9/16) |
Neurogen Corp. (NRGN) |
Aventis SA (France) |
They are ending their collaboration on corticotrophin-releasing factor-based drugs, effective Dec. 8, 2004 |
Termination of the the December 2001 collaboration followed Aventis' merger with Sanofi-Synthelabo; Neurogen regains all rights (9/15) |
Peplin Biotech Ltd. (Australia; ASX:PEP) |
Allergan Inc. |
They ended deal to develop and sell Peplin's PEP005 in North and South America |
The product is targeted at non-melanoma skin cancer; terms of the dissolution were not disclosed (10/8) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.